Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2B, randomized, double blind, placebo-controlled, multicenter study to compare 6 dose regimens of CP-690,550 vs. placebo, each combined with methotrexate, administered for 6 months in the treatment of subjects with active rheumatoid arthritis who have had an inadequate response to methotrexate alone

Trial Profile

A phase 2B, randomized, double blind, placebo-controlled, multicenter study to compare 6 dose regimens of CP-690,550 vs. placebo, each combined with methotrexate, administered for 6 months in the treatment of subjects with active rheumatoid arthritis who have had an inadequate response to methotrexate alone

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Nov 2018 Results assessing Short-, Mid-, and Long-term Effects of Tofacitinib on Lymphocytes in RA patients using data from NCT00853385, NCT01039688, NCT00147498, NCT00413660, NCT00550446, CT02147587 and NCT00413699 sub-studies), published in the Arthritis and Rheumatology
    • 16 Jun 2018 Results of pooled data from 4 Phase 2 trials (NCT00413660; NCT00550446; NCT00603512; NCT00687193) and 5 Phase 3 randomised, double-blind, placebo-controlled trials (ORAL Scan [NCT00847613]; ORAL Solo [NCT00814307]; ORAL Sync [NCT00856544]; ORAL Standard [NCT00853385]; ORAL Step [NCT00960440]), were presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 08 Nov 2017 Results (n=2673) of post-hoc analysis assessing the impact of inflammation severity at baseline on efficacy and safety of tofacitinib using pooled data from four phase II trials (NCT00413660, NCT00550446, NCT00603512, NCT00687193) and five phase III trials (ORAL Scan, ORAL Solo, ORAL Sync, ORAL Standard, ORAL Step), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top